Literature DB >> 9145825

An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots.

S M Palmer1, M J Rybak.   

Abstract

The activity of piperacillin/tazobactam, ampicillin/sulbactam, imipenem and nafcillin alone and in combination with vancomycin was compared with vancomycin monotherapy against MRSA in test-tube time-kill studies and in infected fibrin clots. Bactericidal activity was achieved with all regimens except nafcillin monotherapy in test tubes but only with imipenem/vancomycin and nafcillin/vancomycin in fibrin clots infected with heterogeneous strains. No regimen was effective against the homogeneous strain. These agents may have potential as alternatives to vancomycin in selected infections.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9145825     DOI: 10.1093/jac/39.4.515

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model.

Authors:  R L Akins; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

3.  In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains.

Authors:  S Rochon-Edouard; M Pestel-Caron; J F Lemeland; F Caron
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

4.  β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone.

Authors:  Thomas J Dilworth; Omar Ibrahim; Pamela Hall; Jora Sliwinski; Carla Walraven; Renée-Claude Mercier
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

5.  In vitro activities of co-amoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus: a controlled study with vancomycin.

Authors:  J Prieto; L Aguilar; M J Giménez; D Toro; M L Gómez-Lus; R Dal-Ré; I P Balcabao
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

6.  Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.

Authors:  Thomas J Dilworth; Jora Sliwinski; Keenan Ryan; Monique Dodd; Renée-Claude Mercier
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

7.  Thermo-responsive triple-function nanotransporter for efficient chemo-photothermal therapy of multidrug-resistant bacterial infection.

Authors:  Guangchao Qing; Xianxian Zhao; Ningqiang Gong; Jing Chen; Xianlei Li; Yaling Gan; Yongchao Wang; Zhen Zhang; Yuxuan Zhang; Weisheng Guo; Yang Luo; Xing-Jie Liang
Journal:  Nat Commun       Date:  2019-09-24       Impact factor: 14.919

8.  CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.

Authors:  Steven Y C Tong; Jane Nelson; David L Paterson; Vance G Fowler; Benjamin P Howden; Allen C Cheng; Mark Chatfield; Jeffrey Lipman; Sebastian Van Hal; Matthew O'Sullivan; James O Robinson; Dafna Yahav; David Lye; Joshua S Davis
Journal:  Trials       Date:  2016-03-31       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.